Key Points
- Director Robert Hombach bought 13,000 shares of Seaport Therapeutics at an average price of $18.14 per share, a transaction worth $235,820.
- After the purchase, Hombach directly owned 13,000 shares, and the filing with the SEC disclosed the insider trade.
- Seaport Therapeutics last reported quarterly EPS of ($10.34), beating estimates, while analysts currently have a Hold consensus and an average price target of $35.50.
Seaport Therapeutics, Inc. (NASDAQ:SPTX - Get Free Report) Director Robert Hombach bought 13,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $18.14 per share, with a total value of $235,820.00. Following the completion of the purchase, the director directly owned 13,000 shares in the company, valued at approximately $235,820. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
Seaport Therapeutics Price Performance
Seaport Therapeutics stock opened at $19.31 on Thursday. Seaport Therapeutics, Inc. has a 1 year low of $14.85 and a 1 year high of $23.00.
Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last posted its quarterly earnings results on Monday, June 8th. The company reported ($10.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.64) by $0.30.
Analysts Set New Price Targets
SPTX has been the subject of several research reports. Wall Street Zen raised shares of Seaport Therapeutics to a "hold" rating in a research report on Saturday, May 9th. Leerink Partners started coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They set an "outperform" rating and a $35.00 target price for the company. Seaport Research Partners set a $42.00 price target on Seaport Therapeutics in a research note on Tuesday, May 26th. Stifel Nicolaus initiated coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They issued a "buy" rating and a $30.00 price target on the stock. Finally, Citigroup assumed coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They set a "buy" rating and a $35.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Seaport Therapeutics currently has a consensus rating of "Hold" and an average target price of $35.50.
View Our Latest Report on SPTX
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
